Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03306836
Other study ID # 2016YFC1301800-2
Secondary ID
Status Recruiting
Phase N/A
First received May 31, 2017
Last updated October 10, 2017
Start date September 2016
Est. completion date August 2021

Study information

Verified date October 2017
Source Beijing Tiantan Hospital
Contact Yong Cao, Doctor
Phone 010-67096510
Email caoyong6@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In the stage of randomized controlled study, our purpose is to obtain the Intraoperative anticoagulation program supported by evidence-based medicine.


Description:

This study is divided into anticoagulation program in cerebral aneurysm with hybrid operation and anticoagulation program in cerebral arteriovenous malformations with hybrid operation two parts, and each part divide into two stage, on the stage of registration study. This study is a multi-center, single-blind, prospective cohort study. Record the patient's intraoperative activated coagulation time Changes in detail, to observe the effect of activated coagulation time maintenance level on hemorrhage event rate of Intraoperative and postoperative 48 hours, purpose to find out the safety range of activated coagulation time level in cerebral aneurysm and arteriovenous malformations with hybrid operation. On the stage of randomized controlled study. This study is a multicenter, single-blind, prospective, randomized controlled study. Patients is divided into intraoperative standard dose group of Heparin Sodium and low dose group of Heparin Sodium randomly. To observe the effect of different anticoagulation regimens on activated coagulation time safety coverage rate during surgery, and finally develop a scientific and effective intraoperative anticoagulant therapy program.


Recruitment information / eligibility

Status Recruiting
Enrollment 408
Est. completion date August 2021
Est. primary completion date September 2020
Accepts healthy volunteers No
Gender All
Age group N/A to 70 Years
Eligibility Inclusion Criteria:

1.All patients undergoing hybird surgery.

Exclusion Criteria:

1. Poor general condition , severe primary disease, surgical contraindications

2. Patient or family refused surgery

3. Fusiform aneurysm,Traumatic aneurysm,Infectious aneurysms

4. Combined with other hemorrhagic cerebrovascular disease

5. Combined with malignant brain tumor

6. Perinatal, Pregnancy

7. Patients unwilling to participate in the trial

Study Design


Intervention

Drug:
Heparin Sodium
Infused with 5000 IU of Heparin Sodium
Heparin Sodium
Infusion Heparin Sodium at a rate of 18 IU / kg.h

Locations

Country Name City State
China Beijing Tiantan Hospital, Capital Medical University Beijing Beijing

Sponsors (6)

Lead Sponsor Collaborator
Beijing Tiantan Hospital First Affiliated Hospital of Fujian Medical University, Fujian Medical University Union Hospital, Kunming Medical University, Nanjing PLA General Hospital, Tang-Du Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in activated coagulation time safety coverage rate from the beginning of surgery to 48 hours after surgery Activated coagulation time average value falls in the safety coverage rate from the beginning of surgery to 48 hours after surgery. From the beginning of surgery to 48 hours after surgery
Secondary Changes in hemorrhage event rate from the beginning of surgery to 48 hours after surgery Hemorrhage event include intracranial hemorrhage caused by non-surgical reasons, as well as other organs or parts of the massive bleeding or small bleeding, Including subperitoneal hemorrhage, intraocular hemorrhage, gross hematuria, epistaxis time prolonged or repeated, gastrointestinal bleeding, hemoptysis, subconjunctival hemorrhage, hematoma greater than 5cm, bleeding difficult to control the and so on. From the beginning of surgery to 48 hours after surgery
Secondary Changes in ischemia event rate from the beginning of surgery to 48 hours after surgery Ischemia event include Cerebral infarction and transient ischemic attack. From the beginning of surgery to 48 hours after surgery
Secondary Intraoperative blood loss All the blood lost during the surgery should be collected and measured. From the beginning of surgery to 48 hours after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT04583163 - Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients
Recruiting NCT03306823 - Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 1 N/A
Recruiting NCT02345395 - Safety Study of Minimally Invasive Approaches to Unruptured Anterior Circulation Aneurysms N/A
Completed NCT00962546 - Computed Tomographic (CT) Perfusion and CT Angiography as Screening Tools for Vasospasm Following Subarachnoid Hemorrhage N/A
Recruiting NCT04141020 - Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms Phase 2
Recruiting NCT01460563 - Valproic Acid, Magnesium Sulphate, Rocuronium Requirement, Postoperative Analgesia N/A
Completed NCT02507999 - Goal-directed Therapy in Endovascular Coiling of Cerebral Aneurysm Patients N/A
Recruiting NCT02162654 - Remote Ischemic Preconditioning for Intracranial Aneurysm Treatment N/A
Completed NCT01943591 - DELTA Trial: Does Embolization With Larger Coils Lead to Better Treatment of Aneurysms Trial N/A
Recruiting NCT03815149 - Safety and Clinical Effectiveness of Pipeline™ Shield Devices for Intracranial Aneurysms
Completed NCT03152201 - New Findings About Somatosensory Evoked Potentials (SEP) During Surgery for Cerebral Aneurysms
Recruiting NCT02444832 - Multicenter Retrospective Registry of Anterior Communicating Artery Aneurysms With Endovascular Therapy N/A
Active, not recruiting NCT05774782 - Parent Artery Reconstruction for Cerebral Aneurysms Using a Novel Flow Diverter With Surface Modification N/A
Withdrawn NCT01878136 - Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage Phase 1/Phase 2
Withdrawn NCT02011321 - Clevidipine for Vasospasm After Subarachnoid Hemorrhage (SAH) Phase 2
Completed NCT02455440 - Esmolol Infusion in Patients Undergoing Craniotomy Phase 3
Completed NCT00614887 - Hypothalamo-, Pituitary-, Adrenal Axis Dysfunction in Subarachnoid Hemorrhage
Terminated NCT02281721 - Surpass Flow Diverter for Intracranial Aneurysms: SURMOUNT Registry Data Collection
Completed NCT04963933 - A Medical Device to Treat Brain Aneurysms N/A
Completed NCT02700607 - Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity N/A